Is a Six-Month Wet AMD Shot Finally Here?
A six-month wet AMD shot is close but not here yet. Zenkuda, a new anti-VEGF drug from Kodiak Sciences, matched Eylea for vision gains in a Phase 3 trial with more than half of patients dosed only every six months. The results come from a company press release and haven't been peer reviewed, and the drug isn't FDA-approved yet. But for anyone worn out by the frequent injections of wet AMD care, this is the first Phase 3 result showing a majority of patients can hold their vision on a shot every six months.
Wet AMD is a disease where the treatment works and the schedule fails. Getting an injection every four to eight weeks, forever, is a lot to sustain. In routine care, the visits drift, the shots stretch, and the early gains reverse. DAYBREAK asked whether cutting the schedule to twice a year could hold up.
Why the injection schedule matters
Left alone, wet AMD is one of the fastest ways to go legally blind. A meta-analysis of untreated eyes in pre-anti-VEGF interventional trials found the proportion with vision worse than 20/200 rose from about 20% at baseline to roughly 76% by three years. A modeling study estimated that monthly anti-VEGF injections cut the two-year rate of legal blindness by roughly 72% versus no treatment. That benefit depends on people getting the injections on schedule.
They often don't. In one large real-world registry, patients getting 4 or fewer injections in the first year lost vision on net, and those getting more gained. In a larger US registry, each additional first-year injection was worth about two-thirds of a letter at 12 months. A European registry found about 25% of patients need shots every six weeks, and roughly 40% discontinue treatment by year two. In another US cohort, the initial letter gain reversed into a 5-letter net loss by year four as annual injection counts drifted from 7.5 down to 6.4.
What DAYBREAK showed
On September 28, 2026, Kodiak Sciences reported that DAYBREAK, its Phase 3 trial in treatment-naive wet AMD, hit its primary endpoint: Zenkuda produced non-inferior vision gains at one year against aflibercept 2 mg dosed every eight weeks. The dosing is the news. 54% of Zenkuda patients were on a 24-week interval by the end of year one under strict treat-to-dryness retreatment rules. Reported intraocular inflammation was 0%, and the cataract rate was lower than with aflibercept.
Two caveats live inside that result. First, the results come from a company press release and haven't been peer reviewed. The exact letter-gain point estimates, the pre-specified non-inferiority margin, and per-arm sample sizes weren't disclosed. Second, Zenkuda has a mixed Phase 3 history. An earlier trial, DAZZLE, missed its primary vision endpoint against aflibercept in wet AMD. A separate Phase 3, DAYLIGHT, hit its endpoint but reported intraocular inflammation in 3.3% of patients on monthly tarcocimab, versus 0.4% on aflibercept. DAYBREAK is the trial that clears the bar, and it does so on a six-month schedule the others couldn't touch. Kodiak plans to file a Biologics License Application (BLA) with the FDA in the fourth quarter of 2026.
Where Zenkuda would fit if it's approved
The gap between an eight-week schedule and a longer one has already been closing. Faricimab and aflibercept 8 mg both stretch intervals meaningfully without giving up vision. What DAYBREAK adds is a six-month interval for the majority of treatment-naive patients, which is the first Phase 3 to reach that mark.
| Drug | Vision vs Eylea 2 mg | Longest interval reached in pivotal trial | US approval status |
|---|---|---|---|
| Aflibercept 2 mg (Eylea) | Reference | 8 weeks | Approved |
| Faricimab (Vabysmo) | Matched | 16 weeks (TENAYA and LUCERNE) | Approved |
| Aflibercept 8 mg (Eylea HD) | Matched | 24 weeks in a subset (PULSAR, year 2) | Approved |
| Tarcocimab tedromer (Zenkuda) | Matched (press release) | 24 weeks in a majority (DAYBREAK, year 1) | Not approved; BLA planned Q4 2026 |
If wet AMD is already part of your life
If you're currently getting anti-VEGF injections, DAYBREAK doesn't change what to do today. Zenkuda isn't approved, the data come from a press release, and whether to switch drugs mid-treatment depends on how your eye is doing, which is your retina specialist's call.
The part worth acting on now is the injection burden itself. If you're stretching, skipping, or dreading appointments, that pattern is the one tied to the four-to-six-year vision loss the registries keep finding. Two approved options were designed to lengthen intervals: faricimab (Vabysmo) and aflibercept 8 mg (Eylea HD). Both are worth raising with your retina specialist if the schedule is what stands between you and your vision. Zenkuda is worth revisiting once the FDA acts; the filing is expected in late 2026.
DAYBREAK is the first credible signal that six-month intervals are within reach. That could still change if the peer-reviewed data read softer than the press release, if longer-term safety signals from the earlier Zenkuda trials resurface, or if the FDA disagrees with Kodiak's read of the numbers.